Navigation Links
Data Demonstrate that Obagi Medical Products' Condition & Enhance Skin Care System is an Effective Complement to Facial Rejuvenation Procedures
Date:2/1/2008

rocedure to enhance their overall aesthetic result. Mean duration of use of the Condition & Enhance System in this study was 4 weeks pre-conditioning and 6 weeks post-conditioning.

The order and frequency of application of Condition & Enhance are carefully defined and managed by the physician to create a 4-step process for improving and restoring overall skin quality. The first step is skin preparation, the second step is skin correction, the third step is skin stimulation, and the fourth step is skin protection.

"The results of this large-scale study reinforce the efficacy and tolerability of Condition & Enhance, and we are pleased to provide a system that works in concert with some of today's most sought-after facial rejuvenation procedures to help improve clinical outcomes," said Steve Carlson, President & CEO, Obagi Medical Products, Inc.

About Obagi Medical Products, Inc.

Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics(TM) technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm, 1988; Obagi-C Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi Professional-C (a line of highly stable vitamin C serums), 2005; Obagi Nu-Derm Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm eye treatment and Obagi CLENZIderm M.D. acne therapeutic systems, 2007; and a formulation of CLENZIderm for normal to dry skin, June 2007. Obagi's products are only available through physicians. Visit http://www.obagi.com<
'/>"/>

SOURCE Obagi Medical Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
7. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
8. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... HILL, N.C. , Aug. 1, 2014  With ... is learning to speak a second language. Clinical efficacy ... new agencies established under the ACA like PCORI are ... With a variety of new entities and environments, the ... to speak the new language of outcomes and managed ...
(Date:8/1/2014)... -- In the latest call for gender equity in ... 60 doctors and leading medical experts from across the ... and Drug Administration,s (FDA) decision to approve 26 drugs ... dysfunction compared with ZERO for women,s most common complaint, ... by approving the first-ever drug to treat Hypoactive Sexual ...
(Date:8/1/2014)... 2014 According to the ... Closure, Anti infective), Basic (Films, Cleansing), Advanced (Hydrogels, ... Substitutes), Pressure Relief Devices, NPWT) - Global Forecast ... Market is expected to reach $18.3 Billion by ... a CAGR of 3.2% from 2014 to 2019. ...
Breaking Medicine Technology:Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 360+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3
... to Four Years of Treatment Presented at ICAAC/IDSA,2008 ... (NYSE: SGP ) today reported a data ... demonstrated,sustained viral suppression and increased CD4 cell counts ... of therapy in treatment-experienced,HIV-infected patients. Vicriviroc was administered ...
... Pharmaceuticals, Inc. today,announced positive Phase 2 data for ... (AMC). The Phase 2 study compared,safety and efficacy ... 0796 to,Zyvox(R) in the treatment of patients with ... met its primary safety and,tolerability endpoint, demonstrating no ...
Cached Medicine Technology:Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 2Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 3Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 4Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 5Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 6Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:8/1/2014)... 01, 2014 The evolving healthcare ... community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good ... practices and resources to enhance patient care and ... on critical issues to give independent pharmacists the ... , ThoughtSpot show attendance experienced a nearly ...
(Date:8/1/2014)... 1, 2014Lesbian, gay, bisexual, and transgender individuals who want ... as some of their heterosexual and cisgendered peers, such ... additional physiological and legal challenges to become parents. ... assisted reproduction options is presented in the article " ... published in LGBT Health , a ...
(Date:8/1/2014)... August 01, 2014 The American ... Gregg Harper (R-MS), and Peter Welch (D-VT), for ... Medicare Telehealth Parity Act of 2014, which improves ... this effort to improve healthcare access and affordability ... officer of ATA. "These cost-saving provisions are critical ...
(Date:8/1/2014)... 01, 2014 Market Publishers Ltd ... have been added to its catalogue. , ... Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), ... industry drivers include, among others, increasing ageing population, ... In 2015, the pharma market in India is ...
(Date:8/1/2014)... BEACH, FL (PRWEB) August 01, 2014 ... the 2014 California NextGen User Symposium in San Francisco, ... was held at the JW Marriott Union Square hotel. ... help practices get up to speed with ACA compliance ... earlier this month. The symposium provides attendees guidance with ...
Breaking Medicine News(10 mins):Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2
... the supermarket as well as the drugs cupboard when it ... published in the October issue of IJCP, the International Journal ... ask their doctors whether they should apply honey to their ... is one of the oldest foods in existence and was ...
... (ANSA) Organizes Artists Sign-On Letter as Part of Center for Health ... ... ANGELES, Oct. 17 Last week, 39 celebrity activists,and Artists for a ... improve the President,s Emergency Plan for AIDS Relief,(PEPFAR). PEPFAR currently restricts 1/3 ...
... Hall,founder of The Hall Center in Santa Monica, CA, ... of her patients. It wasn,t until she became,immersed in ... investigating her birth control patients more carefully.,"I was shocked ... patients on the,pill, had hormone levels that were on ...
... DUBLIN, Calif., Oct. 17 SuperGen Inc.,(Nasdaq: ... discovery, rapid,development and commercialization of therapies for solid ... have,been accepted for poster presentations at the AACR-NCI-EORTC ... in San Francisco. The poster presentations will ...
... Bulletin Board: HFIT), a leading employee health improvement company,will ... 30,2007, on Monday, November 5, 2007, after the market ... conference call to discuss the results the,same day. Participating ... and,Chief Executive Officer, and Wes Winnekins, Chief Financial Officer. ...
... IRIDEX,Corporation (Nasdaq: IRIX ) announced today that ... Executive Officer, and as a member of,the Board of ... of,Directors has appointed Theodore A. Boutacoff, who is currently ... serve as the Company,s President,and Chief Executive Officer. Prior ...
Cached Medicine News:Health News:Patients should ask surgeons about using honey to heal wounds 2Health News:39 Noted Performing Artists Urge Congress to Fix Flaws in President's Global AIDS Plan 2Health News:Do Not Take the Pill! Dr. Prudence Hall Tells her Teen and Female Patients 2Health News:Do Not Take the Pill! Dr. Prudence Hall Tells her Teen and Female Patients 3Health News:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 2Health News:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 3Health News:Health Fitness Corp. to Report Third Quarter 2007 Financial Results on November 5, 2007 2
Lab-Reader...
Fully automatic NRTL and CE certified microplate reader....
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
EL301 Microwell Strip Reader is a portable, rugged, single/dual wavelength photometer designed to measure and interpret the absorbances of microwell strip assays....
Medicine Products: